Amendments to the Claims

1. (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form excepting a nanoparticle suspension, comprising micronized (R)- 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (hereinafter referred to as "AS-3201") having a mean particle size in a range of above 1 μm to less than about ~~20~~ 10 μm in a ratio of about 0.5% by weight to about 25% by weight of the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

2. (Cancelled)

3. (Original) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

4. (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is in the range of ~~above 1 μm - about 3 μm~~ about 1.2 μm to about 3 μm.

5. (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form excepting a nanoparticle suspension, which comprises micronized AS-3201 having a mean particle size in a range of above 1 μm to less than about ~~20~~ 10 μm in a ratio of about 0.5% by weight [[-]] to 5% by weight, a diluent in a ratio of about 51% by weight [[-]] to about 93.8% by weight, a disintegrator in a ratio of about 5% by weight [[-]] to about 35% by weight, a binder in a ratio of about 0.5% by weight [[-]] to about 5% by weight, and a lubricant in a ratio of about 0.2% by weight [[-]] to about 4% by weight, relative to the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

6. (Cancelled)

7. (Original) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

8. (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is in the range of ~~above 1 μm - about 3 μm~~ about 1.2 μm to about 3 μm.

9-12. (Cancelled)

13. (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form excepting a nanoparticle suspension, which comprises micronized AS-3201 having a mean particle size in a range of above 1 μm to less than about ~~20~~ 10 μm in a ratio of more than 5% by weight and less than about 25% by weight, a diluent in a ratio of about 16% by weight [[-]] to about 84.3% by weight, a disintegrator in a ratio of about 10% by weight [[-]] to about 50% by weight, a binder in a ratio of about 0.5% by weight [[-]] to about 5% by weight, and a lubricant in a ratio of about 0.2% by weight [[-]] to about 4% by weight, relative to the total weight of the pharmaceutical composition,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved within 15 minutes from the start of the method.

14. (Cancelled)

15. (Original) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

16. (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is in the range of ~~above 1μm - about 3 μm~~ about 1.2 μm to about 3 μm.

17-82. (Cancelled)

89. (Currently Amended) A fast-dissolving pharmaceutical composition in a solid dosage form excepting a nanoparticle suspension, comprising micronized ~~AS-3201~~ (R)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (hereinafter referred to as "AS-3201") having a mean particle size of in a range of above 1 μm to less than about ~~20~~ 10 μm in a ratio of about 0.5% by weight to about 25% by weight of the total weight of the pharmaceutical composition, and as a stabilizer at least one acidic substance having ~~an acidity more potent than that of AS-3201,~~ a pKa less than about 5.6,

wherein when a dissolution percentage of AS-3201 from the composition is measured according to the Paddle method, 50% or more of the AS-3201 in the composition is dissolved with 15 minutes from the start of the method.

90. (Currently Amended) The fast-dissolving pharmaceutical composition according to claim 89, wherein the acidic substance is ~~a member selected from the group consisting of citric acid, tartaric acid, maleic acid and phosphoric acetate~~ tartaric acid.

91. (Cancelled)

92. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is above about 1.2 μm.

93. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is above about 1.5 μm.

94. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.2 μm to about 5 μm.

95. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μm to about 5 μm.

96. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μm to about 3 μm.

97. (New) The fast-dissolving pharmaceutical composition according to claim 1, wherein the solid dosage form is tablets, capsules, granules or powder.

98. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is above about 1.2 μm.

99. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is above about 1.5 μm.

100. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.2 μm to about 5 μm.

101. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μm to about 5 μm.

102. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μm to about 3 μm.

103. (New) The fast-dissolving pharmaceutical composition according to claim 5, wherein the solid dosage form is tablets, capsules, granules or powder.

104. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is above about 1.2 μm.

105. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is above about 1.5 μm.

106. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.2 μm to about 5 μm.

107. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μm to about 5 μm.

108. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μm to about 3 μm.

109. (New) The fast-dissolving pharmaceutical composition according to claim 13, wherein the solid dosage form is tablets, capsules, granules or powder.

110. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is above about 1.2 μm.

111. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is above about 1.5 μm.

112. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is less than about 5 μm.

113. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.2 μm to about 5 μm.

114. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μm to about 5 μm.

115. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.2 μm to about 3 μm.

116. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the mean particle size of the micronized AS-3201 is in the range of about 1.5 μm to about 3 μm.

117. (New) The fast-dissolving pharmaceutical composition according to claim 89, wherein the solid dosage form is tablets, capsules, granules or powder.